Short- and Long-term Pulmonary Outcome of Palivizumab in Children Born Extremely Prematurely
| Autor: | Eytan Kaplan, Huda Mussaffi, Lea Sirota, Guy Steuer, Patrick Stafler, Gil Klinger, Hannah Blau, Ephraim Bar-Yishay, Dario Prais, Meir Mei-Zahav |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Pulmonary and Respiratory Medicine
Palivizumab Male Pediatrics medicine.medical_specialty medicine.medical_treatment Birth weight Respiratory Tract Diseases Respiratory Syncytial Virus Infections Critical Care and Intensive Care Medicine Antiviral Agents Chemoprevention Severity of Illness Index Pulmonary function testing 03 medical and health sciences 0302 clinical medicine medicine Humans Lung volumes 030212 general & internal medicine Longitudinal Studies Prospective Studies Child Respiratory Tract Infections Bronchopulmonary Dysplasia Mechanical ventilation business.industry Gestational age Length of Stay medicine.disease Hospitalization Cross-Sectional Studies 030228 respiratory system Bronchopulmonary dysplasia Spirometry Case-Control Studies Infant Extremely Premature Gestation Pulmonary Diffusing Capacity Female Seasons Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Chest. 149(3) |
| ISSN: | 1931-3543 |
| Popis: | Palivizumab reduces the severity of respiratory syncytial virus infection in premature infants, but whether there is a protective effect beyond the preschool age is unknown. This study sought to assess the short- and long-term effects of palivizumab immunization on respiratory morbidity and pulmonary function at school age in children born extremely prematurely.Infants born before 29 weeks' gestation in 2000 to 2003 were assessed at school age by parental questionnaire, hospital chart review, and lung function tests. Children born immediately before the introduction of routine palivizumab prophylaxis were compared with age-matched children who received palivizumab prophylaxis during the first respiratory syncytial virus season.Sixty-three children with a mean age 8.9 years were included: 30 had received palivizumab and 33 had not (control subjects). The groups were similar in terms of gestational age, birth weight, need for mechanical ventilation, and oxygen supplementation. Fifty-three percent of the palivizumab group, compared with 39% of the control group, had bronchopulmonary dysplasia (P = .14). Wheezing occurred in the first 2 years of life in 27% of the palivizumab group and in 70% of control subjects (P = .008); respective hospitalization rates were 33% and 70% (P = .001). At school age, rates of hyperresponsiveness (provocative concentration leading to a 20% fall in FEV11 mg/mL) were 33% and 48%, respectively (P = .38). Spirometry, lung volumes, diffusion, and exhaled nitric oxide were within normal limits, with no significant differences between groups.Palivizumab prophylaxis was associated with reduced wheezing episodes and hospitalizations during the first 2 years of life in children born extremely prematurely. However, it did not affect pulmonary outcome at school age. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|